CN112533601B - Eaat2活化剂及其使用方法 - Google Patents
Eaat2活化剂及其使用方法 Download PDFInfo
- Publication number
- CN112533601B CN112533601B CN201980052147.6A CN201980052147A CN112533601B CN 112533601 B CN112533601 B CN 112533601B CN 201980052147 A CN201980052147 A CN 201980052147A CN 112533601 B CN112533601 B CN 112533601B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- independently selected
- compound
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680423P | 2018-06-04 | 2018-06-04 | |
| US201862680418P | 2018-06-04 | 2018-06-04 | |
| US62/680,423 | 2018-06-04 | ||
| US62/680,418 | 2018-06-04 | ||
| PCT/US2019/035452 WO2019236625A1 (en) | 2018-06-04 | 2019-06-04 | Eaat2 activators and methods of using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112533601A CN112533601A (zh) | 2021-03-19 |
| CN112533601B true CN112533601B (zh) | 2024-08-16 |
Family
ID=68771005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980052147.6A Active CN112533601B (zh) | 2018-06-04 | 2019-06-04 | Eaat2活化剂及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11702403B2 (https=) |
| EP (2) | EP4685140A1 (https=) |
| JP (2) | JP2021527636A (https=) |
| CN (1) | CN112533601B (https=) |
| AU (1) | AU2019282231B2 (https=) |
| CA (1) | CA3102762A1 (https=) |
| ES (1) | ES3041367T3 (https=) |
| IL (1) | IL279199B1 (https=) |
| WO (1) | WO2019236625A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN113939295B (zh) * | 2019-03-20 | 2025-05-16 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260756A (en) * | 1979-11-15 | 1981-04-07 | American Cyanamid Company | 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines |
| US4404203A (en) * | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4397854A (en) * | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| CA2742411A1 (en) * | 2000-09-18 | 2002-03-21 | Eisai R&D Management Co., Ltd. | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| AUPR606401A0 (en) * | 2001-07-02 | 2001-07-26 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| JP2003313169A (ja) * | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
| ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| JP4890439B2 (ja) * | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| AU2008219166B2 (en) * | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| US8426412B2 (en) | 2008-04-08 | 2013-04-23 | Dow Agrosciences, Llc. | 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| US9447075B2 (en) * | 2011-08-02 | 2016-09-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| CN103664895B (zh) * | 2012-08-28 | 2018-02-27 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| AU2013365926B9 (en) * | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP2953944B1 (en) * | 2013-02-07 | 2017-04-26 | Merck Patent GmbH | Pyridazinone-amides derivatives |
| LT2953952T (lt) * | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Makrocikliniai piridazinono dariniai |
| KR102420322B1 (ko) * | 2014-06-17 | 2022-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체 |
| CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| WO2017123991A1 (en) | 2016-01-15 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
-
2019
- 2019-06-04 EP EP25194190.2A patent/EP4685140A1/en active Pending
- 2019-06-04 CN CN201980052147.6A patent/CN112533601B/zh active Active
- 2019-06-04 JP JP2020567510A patent/JP2021527636A/ja active Pending
- 2019-06-04 IL IL279199A patent/IL279199B1/en unknown
- 2019-06-04 EP EP19815032.8A patent/EP3801528B1/en active Active
- 2019-06-04 AU AU2019282231A patent/AU2019282231B2/en active Active
- 2019-06-04 US US16/972,311 patent/US11702403B2/en active Active
- 2019-06-04 WO PCT/US2019/035452 patent/WO2019236625A1/en not_active Ceased
- 2019-06-04 ES ES19815032T patent/ES3041367T3/es active Active
- 2019-06-04 CA CA3102762A patent/CA3102762A1/en active Pending
-
2022
- 2022-10-04 US US17/959,654 patent/US12286420B2/en active Active
-
2023
- 2023-07-18 US US18/354,330 patent/US20240208936A1/en active Pending
-
2024
- 2024-08-09 JP JP2024133796A patent/JP7794910B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
Non-Patent Citations (2)
| Title |
|---|
| RN：1283108-62-2;stn REGISTRY;《STN on the Web REGISTRY数据库》;第1页 * |
| Synthesis of Some Novel 2,6-Disubstituted Pyridazin-3(2H)-one Derivatives as Analgesic,Anti-Inflammatory,and Non-Ulcerogenic Agents;Tamer H.Ibrahim等;《ARCHIV DER PHARMAZIE》;第第350卷卷(第第9期期);权利要求10-12,17 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024160326A (ja) | 2024-11-13 |
| US12286420B2 (en) | 2025-04-29 |
| US20210171497A1 (en) | 2021-06-10 |
| US20230138663A1 (en) | 2023-05-04 |
| ES3041367T3 (en) | 2025-11-11 |
| WO2019236625A1 (en) | 2019-12-12 |
| IL279199A (en) | 2021-01-31 |
| IL279199B1 (en) | 2026-04-01 |
| JP7794910B2 (ja) | 2026-01-06 |
| CN112533601A (zh) | 2021-03-19 |
| EP4685140A1 (en) | 2026-01-28 |
| AU2019282231A1 (en) | 2021-01-14 |
| US20240208936A1 (en) | 2024-06-27 |
| US11702403B2 (en) | 2023-07-18 |
| JP2021527636A (ja) | 2021-10-14 |
| AU2019282231B2 (en) | 2025-04-17 |
| EP3801528A1 (en) | 2021-04-14 |
| EP3801528A4 (en) | 2022-03-09 |
| EP3801528B1 (en) | 2025-08-06 |
| CA3102762A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112533601B (zh) | Eaat2活化剂及其使用方法 | |
| JP7308146B2 (ja) | インターロイキン１受容体関連キナーゼの阻害剤およびその使用 | |
| JP7258748B2 (ja) | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 | |
| KR102083857B1 (ko) | 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도 | |
| JP7590185B2 (ja) | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 | |
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| US11377436B2 (en) | EAAT2 enhancing molecules | |
| KR101839716B1 (ko) | 오렉신 수용체 길항제로서의 (ｓ)-(２-(６-클로로-７-메틸-１ｈ-벤조[ｄ]이미다졸-２-일)-２-메틸피롤리딘-１-일)(５-메톡시-２-(２ｈ-１,２,３-트리아졸-２-일)페닐)메타논의 결정성 염 형태 | |
| CN106146391A (zh) | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 | |
| EP3402793A1 (en) | Pyridazine derivatives as eaat2 activators | |
| JP6903663B2 (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
| CA3160035A1 (en) | Inhibitors of adrenoreceptor adrac2 | |
| JP2021512075A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| EP3668880B1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | |
| CN113105409B (zh) | 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途 | |
| HK40042691B (en) | Eaat2 activators and methods of using thereof | |
| HK40042691A (en) | Eaat2 activators and methods of using thereof | |
| WO2022253270A1 (zh) | 三嗪基甲基环烷基羧酸衍生物及其药物组合物和用途 | |
| KR20200085815A (ko) | 과증식성 질병의 치료를 위한 카페인산 유도체 | |
| EP2784065B1 (en) | Glycine reuptake inhibitor and use thereof | |
| HK40086209A (zh) | 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
| HK40086209B (zh) | 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |